A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
- 9 December 2010
- journal article
- research article
- Published by Elsevier BV in Biological Psychiatry
- Vol. 69 (5), 442-449
- https://doi.org/10.1016/j.biopsych.2010.09.052
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (HHSN278200441003C)
This publication has 48 references indexed in Scilit:
- Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023Biological Psychiatry, 2010
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?Schizophrenia Bulletin, 2010
- The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary StatementsSchizophrenia Bulletin, 2009
- Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in SchizophreniaAmerican Journal of Psychiatry, 2008
- The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and ValidityAmerican Journal of Psychiatry, 2008
- The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and StandardizationAmerican Journal of Psychiatry, 2008
- Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICSSchizophrenia Research, 2004
- Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary studySchizophrenia Research, 2002
- Context-processing deficits in schizophrenia: Converging evidence from three theoretically motivated cognitive tasks.Journal of Abnormal Psychology, 1999
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970